Coin overview
Spot
Fyuchers
Savdo botlari
Nusxa savdosi
Savdo ma'lumotlari
Onchain
Ko'proq
You have enabled the futures cooling-off period (ends at ).
BIO
Ended--
Last price (USDT)
1.79M
24h total (USDT)
5.76M
Total vol (USDT)
2024-12-25 09:00:00 ~ 2025-01-03 09:30:00
Trading time (UTC+0)
2025-01-03 11:00:00 ~ 2025-01-03 15:00:00
Delivery time (UTC+0)
Total supply3.32B
Resources
Introduction
BIO is an open network for biotech acceleration that directs funding to the best early-stage science. With BIO, patients, scientists and biotech builders can collectively fund, build & own portfolios of tokenized biotech projects. BIO protocol provides funding, incentives & liquidity to catalyze an on-chain scientific economy.
Neo (NEO) To Rally Further? Key Emerging Fractal Signaling Potential Upside Move
Date: Mon, Aug 25, 2025 | 05:55 AM GMT The cryptocurrency market is facing fresh volatility as Bitcoin (BTC) retraced to $112K from its 24-hour high of $115K, while Ethereum (ETH) slipped by 1.50%, adding downside pressure across major altcoins. However, Neo (NEO) stood out, surging by an impressive 16% today and extending its weekly rally to 34%. More importantly, NEO’s price chart is flashing a bullish setup that bears a striking resemblance to the breakout structure recently seen in Bio Protocol (BIO). Source: Coinmarketcap NEO Mirrors BIO’s Breakout Structure BIO’s recent move provides a textbook fractal example of how bullish reversals can unfold. After forming a falling wedge — a classic reversal formation — BIO consolidated beneath its 100-day moving average and red resistance zone before reclaiming the 200-day MA and igniting a parabolic rally of more than +300%. NEO now appears to be following a similar path. BIO and NEO Fractal Chart/Coinsprobe (Source: Tradingview) The token has successfully broken out of its falling wedge pattern, reclaimed both the 100-day and 200-day moving averages, and established a support base around the $8.0 red zone. Currently trading at $8.19, NEO is showing encouraging structural strength as buyers defend this breakout level. What’s Next for NEO? If the fractal continues to unfold, holding above the $8.0 support could serve as the launchpad for the next leg higher. The next significant resistance zones lie near $11.41 and $15.42, representing a potential 88% upside from current levels. That said, traders should exercise caution. A breakdown back below the red zone could invalidate the bullish setup, potentially dragging NEO into a prolonged consolidation phase.
Bio: AUBRAI Ignition Sale Oversubscribed by 13.8 Times with Less Than 2 Hours Remaining
According to Foresight News, Bio Protocol announced on X that over 1,660 users have participated in the AUBRAI Ignition Sale, with the subscription rate reaching 13.8 times, and less than two hours remaining until the end. The official statement noted that some frontend issues are being fixed, and if BioXP and BIO have already been deducted from users' wallets, these will be counted in this sale.
Bitget Trading Club Championship (Phase 6)—Grab a share of 80,000 BGB, up to 800 BGB per user!
The Bitget Trading Club Championship (Phase 6) is now live! Trade popular spot assets and share a 80,000 BGB airdrop pool with your club members. Top individual traders can earn up to 800 BGB! Promotion period: August 27, 2025, 12:00:00 AM–September 02, 2025, 11:59:59 PM (UTC+8) Join now Promotion rules: Activity 1: Club credits challenge 1. Daily credits accumulation: earn 1 credit each time your daily buy amount reaches a specified tier. You can earn multiple credits by hitting multiple tiers. For example, you can get 1 credit for buying $200 in a single day, 3 credits for buying $800, 6 credits for buying $6400, and so on. There's no cap on the number of credits you can earn daily! Daily buy amount Daily credits earned 200 1 400 2 800 3 1600 4 3200 5 6400 6 12,800 7 25,600 8 51,200 9 102,400 10 ... ... 2. Incentives calculation: My incentive = my credits ÷ total eligible credits × airdrop pool 3. Eligible trades: all spot-related trades are eligible, excluding stablecoins and zero-fee trading pairs. Eligible types include Bitget spot trading, spot Convert, spot margin trading, and small balance conversion. 4. Users who meet the minimum credit requirement will qualify to share 30,900 BGB. The qualifying threshold will be announced one working day after the promotion via Bitget's official social media channels. Stay tuned! Activity 2: Trading volume leaderboard battle 1. Rules: The user with the highest total spot buy volume during the promotion will receive 800 BGB. The user who ranks 2nd will receive 600 BGB. The total pool is 49,100 BGB, and rankings as well as incentives are as follows. Ranking Incentives 1st 800 BGB 2nd 600 BGB 3rd–5th 400 BGB 6th–10th 300 BGB 11th–50th 150 BGB 51st–100th 100 BGB 101st–300th 50 BGB 301th-1100th 30 BGB 2. Eligible trades: Only trades involving the designated assets (BTC/ETH/BGB/BIO/AAVE) are included. Eligible trading types include spot trading, spot margin trading, spot Convert, and small balance conversion. Note: Users must use the Join Now button to register for the promotion. Only spot orders placed after registration will be counted. This promotion is only open to active Bitget users who reach a total spot trading volume of over $5,000, or a total futures trading volume of over $100,000, or a maximum asset size of over $5,000 within the last 30 days. If you're not yet eligible, feel free to explore other promotions or increase your activity on Bitget to qualify for future promotions. During the promotion, spot orders are tracked daily from 12:00 AM to 11:59 PM (UTC+8) for credit calculation. Credits are awarded based on the actual order execution date. Incentives will be distributed to eligible accounts within five working days after the promotion ends. Users can check their incentives in their spot account. This promotion is exclusive to regular users. Sub-accounts, institutional users, PRO accounts, affiliates, and market makers are not eligible to participate. All participants must strictly comply with Bitget's terms and conditions. Bitget reserves the right to disqualify any user from participating in the promotion and confiscate their incentives if any fraudulent conduct, illegal activities (such as using multiple accounts to claim incentives), or other violations are found. Bitget will conduct a review of all users and promptly disqualify those who employ any technical means, including but not limited to electronic, robotic, repetitive, or automated methods, for the purpose of automated or repeated participation. Due to legal and regulatory requirements, some users may be unable to sign up for a Bitget account, or access may be temporarily restricted in certain countries or regions. Refer to Bitget's terms and conditions for the latest information. Bitget reserves the right to amend, revise, or cancel this promotion at any time without prior notice, at its sole discretion. Bitget reserves the right to the final interpretation of the promotion. Contact customer service if you have any questions. During the promotion period, the trading volume of users with a unified trading account as the main account may not be tracked accurately, which could impact incentive eligibility. We apologize for any inconvenience this may cause. Disclaimer Cryptocurrencies are subject to high market risk and volatility despite high growth potential. Users should conduct their own research and invest at their own discretion. Bitget shall not be liable for any investment losses. Join Bitget, the World's Leading Crypto Exchange and Web3 Company Sign up on Bitget now >>> Follow us on Twitter >>> Join our Community >>>
Bio Protocol’s Aubrai Launch Surpasses Subscription Limits
Key Points: Bio Protocol’s Aubrai project oversubscribed sixfold, impacting token markets. Investor demand exceeds initial expectations. Significant token price movements observed post-launch. Bio Protocol’s Aubrai Launch Surpasses Subscription Limits Bio Protocol’s inaugural BioAgent project, Aubrai, has been oversubscribed sixfold, the company announced through its official channels. The oversubscription indicates high investor demand, significantly affecting BIO token prices and marking a pivotal moment for decentralized science projects. Bio Protocol’s first BioAgent Launch project, Aubrai , has been oversubscribed by six times. This oversubscription indicates strong demand and investor interest, marking a notable moment in the decentralization science (DeSci) community. The core team at Bio Protocol announced “The official announcement was made by Bio Protocol on social media, confirming the oversubscription of the Aubrai project by six times.” via their social media channels, highlighting the high demand for the Aubrai project. Despite the high interest, exact subscription figures from top project stakeholders remain undisclosed. The oversubscription triggered a pro rata allocation due to demand exceeding supply, reflecting intense market interest. Token price rose dramatically post-announcement, with a significant shift noticed within hours of the sale. Following the oversubscription, the BIO token price surged by 37%, revealing the financial community’s confidence in the project’s potential. Such price activity underscores the high stakes tied to the Bio Protocol’s commercial trajectories. Investors are closely monitoring potential technological outcomes from this launch, given existing whale wallet accumulations. Analysts point to a surge in trading volumes and activities as the launch had ripple effects across DeSci markets. The implications of this oversubscription could signal further investment in DeSci technology, considering the precedent set by Bio Protocol. Historical trends suggest ongoing interest will sustain market volatility as similar projects roll out.
Bio Protocol launches Aubrai, the first-ever decentralized AI agent for longevity science
Bio Protocol has introduced Aubrai, the world’s first decentralized BioAgent designed to accelerate longevity research. Summary Co-developed with VitaDAO and informed by Dr. Aubrey de Grey’s longevity research, Aubrai leverages decentralized mechanisms to overcome traditional funding gaps and accelerate translational science. Aubrai can generate and validate research hypotheses, design wet-lab experiments, and securely encrypt data. Bio Protocol ( BIO ) has launched Aubrai, the world’s first decentralized AI agent designed to advance longevity research. The $AUBRAI Ignition Sale is live on Bio! Join the AUBRAI Sale: https://t.co/II8XyzdNwY > Commit $BIO & pledge BioXP before tomorrow Aug 26 11:00 UTC to qualify for an AUBRAI allocation > AUBRAI goes live for open-market trading TOMORROW shortly after the Ignition Sale closes https://t.co/GwZDqvIbGv — Bio Protocol (@BioProtocol) August 25, 2025 The launch price is set at 0.585 BIO per AUBRAI. The ongoing sale, conducted on the BASE blockchain, set a fundraising target of 234,000 BIO and has already been oversubscribed 13.5x. Source: bio.xyz About Bioprotocol’s Aubrai Co-developed by Bio Protocol and VitaDAO, Aubrai is the world’s first decentralized BioAgent, drawing knowledge from thousands of private lab notes, internal chats, and unpublished insights from the lab of Dr. Aubrey de Grey. De Grey is best known for pioneering longevity research through his Strategies for Engineered Negligible Senescence (SENS) framework and advocating the idea that aging is a disease that can be treated. “The consequences of traditional financing are a chronic funding gap, over-reliance on philanthropy, and a ‘valley of death’ between discovery and the clinic. That’s why we champion alternative mechanisms – DAOs, longevity-focused venture funds, and DeSci platforms – which can tolerate long horizons, align incentives around societal benefit, and crowd-source risk,” de Grey told CoinDesk in an interview. Aubrai functions as an on-chain AI co-scientist. It can generate and validate hypotheses, design wet-lab experiments, and encrypt data to protect trade secrets while enriching research outputs. At the heart of Aubrai’s mission is the Robust Mouse Rejuvenation (RMR2) project — de Grey’s ambitious study aiming to double the remaining lifespan of middle-aged mice. Aubrai has already demonstrated its capabilities in the RMR2 study, suggesting methodological tweaks and flagging dosing caveats. AUBRAI token holders gain governance rights over the agent’s research outputs. They also share in potential revenues from discoveries commercialized by the project.
Polygon (POL) To Rally Higher? Key Emerging Fractal Signaling Potential Upside Move
Date: Fri, Aug 22, 2025 | 06:25 PM GMT The cryptocurrency market turned bullish in the last hour after Jerome Powell hinted at potential rate cuts in September during today’s Jackson Hole event. Following the remarks, Ethereum (ETH) surged over 7% past $4,600, fueling strong momentum across altcoins , including Polygon (POL). POL has gained 6% in the past 24 hours, and its chart is now showing a bullish fractal structure that closely mirrors the breakout recently witnessed in Bio Protocol (BIO). Source: Coinmarketcap POL Mirrors BIO’s Breakout Structure BIO’s earlier price action offers a roadmap for POL’s potential. Earlier this year, BIO broke out of a falling wedge pattern, a classic bullish reversal setup. After the breakout, BIO consolidated just under a major resistance zone (highlighted in red). Once it cleared this barrier, the token accelerated sharply, reclaiming multiple resistance levels and ultimately delivering a 240% rally. BIO and POL Fractal Chart/Coinsprobe (Source: Tradingview) POL appears to be tracing the same trajectory. The token has already broken out of its own falling wedge formation and is currently pressing against a critical resistance zone near $0.2635, marked in red on the chart. What’s Next for POL? If this fractal continues to play out, a decisive breakout above $0.2635 could be the spark for a new bullish wave. The next upside targets sit at $0.3345 and $0.5170, representing a potential 104% move higher from current levels, should POL replicate BIO’s explosive pattern.
Saga (SAGA) To Rise Higher? Key Emerging Fractal Signaling Potential Bullish Move
Date: Sun, Aug 24, 2025 | 10:20 AM GMT The cryptocurrency market is taking a breather today after a strong rally triggered by Jerome Powell’s comments at the Jackson Hole event, where he hinted at potential rate cuts in September. Ethereum (ETH) briefly touched a new all-time high of $4,878 before cooling off to around $4,740, but the bullish energy has already sparked momentum across several altcoins . Among them, Saga (SAGA) is drawing attention as its chart structure is beginning to mirror the explosive breakout that recently played out in Bio Protocol (BIO). Source: Coinmarketcap SAGA Mirrors BIO’s Breakout Structure BIO’s price action serves as a textbook example of a fractal in play. After forming a falling wedge, a well-known bullish reversal pattern, BIO consolidated below its 100-day moving average and red resistance zone before reclaiming the 200-day MA and eventually launching into a parabolic rally of more than 300%. BIO and SAGA Fractal Chart/Coinsprobe (Source: Tradingview) Now, Saga’s daily chart appears to be tracing an eerily similar path. The token has already broken out of its own falling wedge and is currently hovering near its 100-day moving average, with immediate resistance at the red horizontal zone and the 200-day MA around $0.3354. This setup strongly resembles the pre-breakout conditions that fueled BIO’s massive upside surge. What’s Next for SAGA? If history repeats and SAGA continues to follow BIO’s fractal, the next key step would be a confirmed breakout above the 200-day MA. A decisive reclaim of this level could trigger strong upside momentum and potentially propel SAGA toward the $1.23 region, mirroring the explosive trajectory of BIO. On the flip side, failure to clear the 200-day MA could keep SAGA trading sideways and delay the bullish scenario. Traders should closely watch how price reacts around these critical moving averages.
Scroll (SCR) To Rally Higher? Key Emerging Fractal Signaling Potential Upside Move
Date: Thu, Aug 21, 2025 | 08:56 AM GMT The cryptocurrency market is bouncing back from its recent dip as Ethereum (ETH) reclaims $4,300, registering a 3% daily gain. This upside momentum is spilling over into altcoins , with Scroll (SCR) emerging as one of the notable movers. SCR surged by an impressive 14% today, and its chart is now flashing a bullish technical setup that strongly resembles the breakout structure seen in Bio Protocol (BIO) in this week. Source: Coinmarketcap SCR Mirrors BIO’s Breakout Structure BIO provides a valuable fractal reference. After forming a falling wedge pattern breakout—a well-known bullish reversal signal—BIO consolidated beneath a red-marked resistance zone before reclaiming multiple resistance levels. The breakout fueled a powerful 124% rally in just weeks. BIO and SCR Fractal Chart/Coinsprobe (Source: Tradingview) Now, SCR is beginning to trace a similar path. The token has broken out of its falling wedge pattern and has established a support foundation around the red zone at $0.347. Currently, SCR is trading above that level at $0.41, signaling strength in its price structure. What’s Next for SCR? If the fractal continues to play out, holding this $0.357 support zone could serve as the springboard for the next rally leg. The next major resistance lies near $0.692, which would represent an 85% upside from current levels. However, traders should remain cautious. A dip back below the red zone support could invalidate the bullish setup and push SCR into deeper consolidation. Disclaimer: This article is for informational purposes only and not financial advice. Always conduct your own research before investing in cryptocurrencies.
Bio Protocol to Launch First BioAgent Sale Project Aubrai, with 20% of Total Supply Allocated for Sale
Foresight News reports that the decentralized science (DeSci) platform Bio Protocol will launch its first BioAgent sale project, Aubrai. Aubrai has a total supply of 2 million tokens, of which 20% will be allocated for sale, 6% for the liquidity pool, 15% for the treasury, 20.1% for initial backers, 10% for LEVF, 22% for VitaDAO, and 6.9% for Bio Protocol. The token TGE is scheduled for August 25. Aubrai is a decentralized scientific agent jointly developed by VitaDAO and BIO, aimed at combating human aging.
Bio Protocol Launches Token Launchpad, Allocation Depends on Staked BioXP Shares
BlockBeats News, August 22 — DeSci protocol Bio Protocol has recently launched a token launch platform, with its first project being Aubrai. Users can obtain allocation for new token issuances by staking BioXP, and can acquire tokens by contributing BIO. The final allocation depends on the amount of BioXP staked. BioXP can be obtained through the following methods: staking Bio or Bio ecosystem assets; social participation (“Yapping”); DeSci score (purchasing ecosystem asset tokens, participating in past and upcoming sales on the Bio token launch platform, etc.); retroactive rewards (participating in Bio auctions to claim BIOXP); and project curation in Bio Protocol V1, among others. The first BioAgent Launch project, Aubrai, will have a 24-hour sale period, with the opening time to be announced separately. The AUBRAI token will be listed immediately after the sale concludes. Additionally, according to market data, BIO’s 24-hour price increase has expanded to 25%, with its market capitalization rebounding to $345 million.
Top 3 Altcoins Accumulated Off Exchanges in Mid-August
By the third week of August, several altcoins experienced a sharp drop in exchange reserves. This trend reflects growing demand for accumulation and off-exchange holding. The shift is especially notable as the so-called altcoin season has become increasingly selective. Which tokens are seeing this surge in accumulation, and what factors drive investor optimism? 1. Ethena (ENA) Data from Santiment shows that Ethena (ENA) exchange reserves fell from 1.3 billion to 1.15 billion during the third week of August. In other words, 150 million ENA left centralized exchanges. This happened while ENA’s price surged 30% in August, climbing from $0.51 to $0.65. ENA Supply on Exchanges. Source: Santiment. The reserve drop coincided with the Ethena Foundation announcing a $260 million buyback program. The plan allocates around $5 million daily to repurchase ENA from the market. Tokenomist estimates the buyback could remove 3.48% of the circulating supply. This absorption of sell pressure boosts long-term investor confidence. In addition, Ethena crossed major milestones in August. Revenue surpassed $500 million, while USDe supply reached a record high of $11.7 billion. Together, these drivers fueled ENA accumulation and exchange reserve declines. 2. BIO Protocol (BIO) BIO Protocol, a leading project in the DeSci sector, delivered an exceptional performance in August with gains of over 265%. Alongside the price rally, exchange reserves fell sharply. From early August to now, reserves dropped from 380 million to 294 million BIO — a more than 22% decline. The third week of August saw the most dramatic movement. Investors withdrew 42 million BIO in just one week, pushing exchange reserves to their lowest level this year. BIO Supply on Exchanges. Source: Santiment. Several catalysts explain this accumulation wave. BIO launched a staking program early in August that attracted over 25 million tokens. Additionally, Arthur Hayes invested $1 million into BIO this week, reigniting market attention. Bio Protocol also rolled out a new way to reach new investors. Users are asked to discuss the project on social media to earn BioXP, which gives them access to the first BioAgent sales. These factors combined to boost visibility, attract new investors, and accelerate accumulation. 3. API3 API3, an oracle-focused project, regained investor interest in August, sending its price up more than 130%. At the same time, exchange reserves fell to their lowest point this year. The third week of August marked a turning point. Over 9 million API3 were withdrawn from exchanges, reducing exchange supply to just 17.19 million. API3 Supply on Exchanges. Source: Santiment. The catalyst was Upbit’s listing of API3. According to the BeInCrypto report, the token’s price jumped over 120% immediately after the listing. Investor focus on the Oracle sector also increased due to Chainlink’s (LINK) rally. LINK’s strong performance in the past month spilled over into related projects. Data from Artemis confirmed Oracle was the market’s best-performing sector in August. The surge in API3 accumulation has kept its price trading steady at above $1.50. These three altcoins highlight different drivers behind August’s selective altcoin rally. While a broad-based altcoin season has yet to emerge, projects with unique catalysts — whether buyback programs, staking incentives, or an exchange listing — are attracting investor attention and capital.
Chromia (CHR) To Rally Higher? Key Emerging Fractal Signaling Potential Upside Move
Date: Thu, Aug 21, 2025 | 06:04 AM GMT The cryptocurrency market is rebounding from the recent pullback as Ethereum (ETH) climbs back to $4,300, posting a 3% daily gain. This momentum has lifted sentiment across the broader altcoin market, including Chromia (CHR). CHR has surged by an impressive 10% in the past 24 hours and is now showing a bullish technical structure that bears a striking resemblance to the breakout recently seen in Bio Protocol (BIO). Source: Coinmarketcap CHR Mirrors BIO’s Breakout Structure BIO’s price action provides a useful roadmap. Earlier this year, BIO broke out of a classic falling wedge pattern—a well-recognized bullish reversal formation. After the breakout, the token consolidated just below a resistance zone (highlighted in red on the chart). Once this barrier gave way, BIO regained strong momentum, reclaiming multiple resistance levels and ultimately delivering a 124% rally. BIO and CHR Fractal Chart/Coinsprobe (Source: Tradingview) Now, CHR is beginning to follow the same path. The token has already broken out of its own falling wedge pattern and is currently testing a critical resistance zone around $0.1083—marked in red on the chart. What’s Next for CHR? If this fractal continues to unfold, a successful breakout above $0.1083 could act as the catalyst for a fresh rally. From there, CHR could climb toward the next resistance levels at $0.1457 and $0.2337—a potential 122% upside from current prices, mirroring BIO’s explosive move.
BIO price forms a golden cross, can it rally to $0.30 as whales buy?BIO price forms a golden cross
BIO price looks poised to confirm a golden cross amid continued whale accumulation. Can it rally to $0.30 in the coming weeks? Summary Bio Protocol is up over 80% in the past week and has hit a six-month high today. Whales and high-profile figures have continued investing in BIO. A golden cross has formed on the daily chart, supported by other bullish technicals. According to data from crypto.news, Bio Protocol ( BIO ) rallied over 80% in the past 7 days, trading at $0.186, its highest level in six months. As of press time, its monthly gains stand at 175% while its year-to-date gains are over 340%. BIO crypto has rallied as whales and public figures show strong demand for the token. As per data from blockchain analytics platform Nansen, the balance of tokens held by whale wallets has increased to 21.94 million, up from 18.72 million recorded 7 days earlier and significantly higher than 2.03 million a month ago. Such strong accumulation by whales is often seen as a vote of confidence in the token’s outlook, creating a feedback loop that draws in retail investors and fuels further price appreciation. Source: Nansen The balance held by public figures has gone up to 7.66 million from just around 3,900 tokens held just a week earlier. BIO token also gained traction as the balance held by exchanges dropped 11.6%, from 471 million on Aug. 15 to just over 414 million at the time of writing. A decline in exchange balances typically suggests that investors are moving tokens into their own wallets, reducing the available supply on trading platforms. This could lower selling pressure and potentially support further price gains. A more recent catalyst that could be driving the token’s gains is the launch of Bio Protocol’s first BioAgent, Aubrai, yesterday, Aug. 21. The debut linked BIO’s utility to real biotech applications , boosting demand for the token. BIO price forms a golden cross BIO price had been consolidating within the $0.040–$0.100 range since early March before breaking out of this accumulation zone in August, following the confirmation of a double-bottom pattern on the daily chart—a formation typically associated with trend reversals and renewed buying momentum. BIO price forms a golden cross after it breaks out of a multimonth accumulation zone on the daily chart — Aug. 22 | Source: crypto.news The breakout has been reinforced by the emergence of a golden cross, as the 50-day simple moving average crossed above the 200-day moving average. This signal is generally viewed as a strong indicator of sustained bullish momentum. Supporting indicators such as the MACD and RSI are also trending higher, underscoring the strength of the ongoing uptrend. BIO MACD and RSI chart — Aug. 22 | Source: crypto.news From a technical perspective, the next key upside target lies near the $0.30 psychological level, which also coincides with the 1.618 Fibonacci extension. A move to this zone would represent an additional 67% advance from current price levels. However, if bullish momentum weakens, a decisive drop below the $0.10 psychological threshold, closely aligned with the 38.2% Fibonacci retracement, would invalidate this bullish setup and suggest a deeper correction.
Phala Network (PHA) To Rally Higher? Key Fractal Pattern Signals Potential Upside Move
Date: Thu, Aug 21, 2025 | 06:45 AM GMT The cryptocurrency market is rebounding from the recent dip as Ethereum (ETH) reclaims $4,300, notching a 3% daily gain. This strength has carried into the broader altcoin market, with Phala Network (PHA) now showing early signs of a potential breakout. PHA climbed 4% in the last 24 hours, and its price structure is beginning to resemble a bullish fractal pattern recently confirmed in Bio Protocol (BIO). Source: Coinmarketcap PHA Mirrors BIO’s Breakout Structure BIO’s chart has become a valuable reference point for traders. Earlier this year, BIO broke out of a classic falling wedge pattern—a bullish reversal formation. After consolidating beneath a red-marked resistance zone, the token powered higher, reclaiming multiple resistance levels and ultimately rallying by an impressive 124%. BIO and PHA Fractal Chart/Coinsprobe (Source: Tradingview) PHA appears to be walking the same path. It has also completed a breakout from a falling wedge structure and is now trading just below its immediate red resistance zone at $0.13, currently priced around $0.1186. What’s Next for PHA? If the fractal continues to play out, a successful breakout above $0.13 could serve as the trigger for a stronger rally. From there, PHA could target the next resistance levels at $0.1625 and $0.2058, which would represent a potential 72% upside from current prices.
Bio Protocol (BIO) To Soar Further? Key Harmonic Pattern Signals Potential Upside Move
Date: Tue, Aug 19, 2025 | 06:50 AM GMT The cryptocurrency market is experiencing notable selling pressure as Ethereum (ETH) slips back to $4,250 from its recent high of $4,780. This weakness has extended to several major altcoins . Yet, despite the broader pullback, Bio Protocol (BIO) has managed to remain resilient, posting a 10% gain on the day and extending its monthly rally to over 100%. Adding to the bullish case, BIO’s chart is now highlighting a harmonic formation that suggests further upside could be on the horizon. Source: Coinmarketcap Harmonic Pattern Hints at Potential Bounce On the 4-hour chart, BIO is forming a Bearish ABCD harmonic pattern. While technically labeled as bearish, this setup usually involves a strong bullish CD-leg rally before the Potential Reversal Zone (PRZ) becomes relevant. The structure began with a rally from Point A near $0.0559 to Point B, before BIO retraced to Point C around $0.0956, where buyers re-entered with conviction. Since then, the token has surged higher and is currently trading near $0.1380, with price action confirming the unfolding of the CD leg. Bio Protocol (BIO) Daily Chart/Coinsprobe (Source: Tradingview) The 1.90 Fibonacci extension of the BC leg projects Point D near $0.1787, marking a key upside target that traders are closely eyeing as the next potential resistance zone. What’s Next for BIO? If bullish momentum continues, BIO could push toward the $0.1787 PRZ, a level that could serve as both a profit-taking zone and a test of market strength. Historically, harmonic patterns often encounter heavy resistance at these completion zones, leading to either consolidation or a corrective pullback.
Memecoin (MEME) To Rally Higher? Key Emerging Fractal Signaling Potential Upside Move
Date: Wed, Aug 20, 2025 | 05:10 PM GMT The cryptocurrency market is staging a notable rebound from the recent dip as Ethereum (ETH) reclaims $4,300, marking a 3.5% daily jump. This strength has spilled over into the major memecoins, including Memecoin (MEME). MEME has entered bullish territory, recording a solid 34% rally in just a single day, and is now flashing a technical setup that closely resembles the breakout structure recently seen in Bio Protocol (BIO). Source: Coinmarketcap MEME Mirrors BIO’s Breakout Structure BIO’s chart offers a valuable reference point. After breaking out of a classic falling wedge pattern—a well-known bullish reversal formation—BIO quickly regained momentum by bouncing off the 100-day moving average. From there, it reclaimed multiple resistance zones and ultimately rallied by nearly 68%. MEME and BIO Fractal Chart/Coinsprobe (Source: Tradingview) Now, MEME is starting to carve out the same path. The token has already broken out of its falling wedge formation and successfully reclaimed its 100-day moving average. This technical move propelled MEME past its first resistance at $0.0026, with the token now trading above it at $0.00275. What’s Next for MEME? If this emerging fractal continues to unfold, MEME could extend its rally toward the next resistance at $0.0038. A short-term retest of the first resistance zone would not be unusual before the token attempts a fresh push higher. Beyond that, a move toward the third resistance at $0.0050 remains possible—representing a potential 73% upside from current levels.
Data: Arthur Hayes Suspected of Accumulating 7.66 Million BIO Tokens Worth Approximately $1.1 Million
According to ChainCatcher, on-chain analyst @ai_9684xtpa has monitored that Arthur Hayes allegedly opened a position of 7.66 million BIO tokens, worth $1.1 million, about half an hour ago. Since August 10, Arthur Hayes has spent a total of $14.37 million to purchase six Ethereum ecosystem tokens. Among them, only PENDLE appears to have been partially sold (the flow cannot be confirmed due to market maker transactions), while the remaining tokens are still being held.
Bio Protocol hits 6-month high as harmonic pattern signals further upside
Bio Protocol funds $80K brain health trial, earning CLAW royalty tokens. Staked BIO tokens rise to 125M, tightening supply and boosting demand. Harmonic chart pattern signals a possible BIO price rally toward $0.1787. The Bio Protocol (BIO) token has regained strong momentum after a sharp pullback earlier this month, climbing to a six-month high of $0.1514 before settling near $0.138. The recovery follows a string of bullish catalysts, ranging from real-world biotech partnerships to a surge in staking activity, while traders are now watching technical signals that hint at further upside. BIO price recovery sparks fresh momentum After dropping to $0.0962 during the recent correction, BIO has staged an impressive rebound of more than 50% in a matter of days. The strong recovery comes at a time when the broader crypto market has been under selling pressure, yet Bio Protocol has managed to move against the trend. At press time, the token was trading nearly 100% higher on the month, underscoring its growing resilience. Trading activity has also intensified. Daily volumes have spiked by more than 700% last week, crossing $440 million as new investors piled in. This sharp increase in liquidity has strengthened confidence that BIO’s market depth is improving, making it more attractive for both retail and institutional traders. Clinical trial funding lifts sentiment One of the strongest drivers of BIO’s price rally has been the announcement of its first major biotech initiative. Through its partner Cerebrum DAO, the Bio Protocol community approved $80,000 in funding for a Phase 2 human clinical trial of Percepta, a supplement targeting memory loss and neurodegeneration. Big week in the Biosphere 🧪 • Launched Bio Markets w/ real-time DeSci analytics & BioAgent trading coming • 125M+ $BIO staked + 1M BioXP Boost • Funding human trial for Percepta $CLAW • Molecule V2 DeSci equity • $BeeARD psilocybin derivative Read the full weekly update: https://t.co/l5lH2Utcjo — Bio Protocol (@BioProtocol) August 17, 2025 The deal not only gives Bio Protocol direct exposure to real-world biotech outcomes but also provides it with CLAW tokens. These tokens are tied to royalties from Percepta sales, creating a potential revenue-sharing model that sets BIO apart from other speculative altcoins. Investors see this as a sign that the project is delivering on its promise to link decentralised finance with biotech innovation. BIO token staking reduces supply pressure Another factor supporting BIO’s price is the steady growth in token staking. The amount of staked BIO tokens has climbed to 125 million, representing about 3.5% of the circulating supply. This is a significant jump from 25 million staked tokens earlier in August. By staking, holders earn BioXP, which provides access to new ecosystem assets such as CLAW. More importantly, staking reduces the liquid supply on exchanges. As a result, when demand rises, the price impact is magnified. Traders are already drawing comparisons to earlier DeFi tokens where similar dynamics sparked explosive rallies. Technical setup points to higher targets From a technical perspective, BIO has cleared several key resistance levels. It moved above the 7-day simple moving average at $0.116 and broke through the 23.6% Fibonacci retracement at $0.128. The next resistance sits near $0.145, with momentum indicators suggesting strong buying pressure despite a relative strength index that hovers near overbought territory. Adding to this outlook, analysts have identified a harmonic ABCD pattern unfolding on the 4-hour chart. The harmonic ABCD pattern began with a rally from $0.0559 to $0.0956 before retracing and launching into a bullish CD-leg. The extension of this structure projects an upside target near $0.1800, which traders are closely monitoring as the next profit-taking zone. Bio Protocol price outlook remains cautiously bullish While the harmonic setup points to further upside, traders remain alert to the possibility of consolidation. A failure to hold above the 50-period moving average, currently near $0.1159, could open the door to short-term corrections. Still, the combination of real-world utility, staking-driven scarcity, and a favourable technical structure has left sentiment firmly bullish. Bio Protocol’s six-month high marks an important milestone for a token launched less than a year ago. But whether it can sustain this rally will depend on both the outcome of the Percepta trial and the broader adoption of decentralised science models.
Can BIO's V2 Launch Revive the Desci Hype?
Once considered a pioneer in the integration of research and cryptography, the leading project in the DeSci track, $BIO, has been under pressure since its launch in January this year—despite the backing of top investors including Vitalik and CZ, it has still been unable to escape the double impact of the market and liquidity, with its market value shrinking by 95% from its all-time high at one point, becoming the focus of community dissatisfaction and questioning, and causing the track that once produced billion-dollar market cap myths like $RIF and $URO to fall into a slump. However, with the recent official launch of BIO Protocol V2, introducing new mechanisms such as the Launchpad and staking points, the total staked amount exceeded 100 million BIO within the first week of launch, and the market value quickly doubled to surpass $2 billion, once again igniting the market's attention and imagination for the DeSci track. Why Has the Once-Prominent $BIO Fallen from Grace? The listing story of BIO was originally a highlight of the DeSci track: A-list exchanges such as Binance, OKX, Kraken, etc., all participated, with a first-day trading volume exceeding $20 billion, and a FDV once reaching $250 million, making it the most sensational scientific crypto asset issuance in early 2025. However, behind the excitement lay the seeds of a price collapse. However, the heat of this feast did not last long. BIO was issued through an auction model, with the initial circulation ratio higher than most new coins, coupled with an inflated valuation upon listing, making it appear overpriced in the absence of immediate utility. Early market buyers were more drawn to the narrative and emotion rather than the practical value. When key features such as the Launchpad, staking system, BioXP points, and other critical functions were still in the planning stage, investors quickly found that their tokens did not bring immediate returns in terms of participation rewards or governance rights. The disconnect between valuation and utility became the first force causing the price to plummet from its peak. The downturn of BIO is also closely related to timing issues. The core features did not go live on the TGE day, leading to a loss of market confidence during the waiting period. Furthermore, in terms of ecosystem expansion, the independent operation of Molecule Catalyst's Launchpad dispersed funds and attention, weakening the cohesion of the main platform. In addition, as the macro market entered a phase of reduced risk appetite, funds quickly moved away from projects with high FDV and no immediate cash flow. The lack of ongoing fundamental support and alignment of product development pace led BIO from a star project at the beginning of the year to gradually fall into a low trading volume and price slump. The Resurgence of BIO Protocol Building a Research Acceleration Lab In the first half of 2025, BIO Protocol went through a rollercoaster journey—from the narrative peak at the beginning of the year to a price slump, but its pace did not slow down. Not only did it deliver outstanding market performance in the DeSci track, but it also pushed several biopharmaceuticals to the brink of clinical trials, allowing "on-chain research" to experience the real breath of medical validation for the first time. The price retracement did not deter the team's ambition, but instead led to more development actions: in May, through community governance, BIO postponed the unlocking of team and advisor tokens, signaling to the market "we are here for the long haul." The research progress also caught people's attention—VitaRNA and VitaFAST both commenced clinical trials in the UAE, taking only 11 months from concept to enrollment, while the traditional model often takes 4–6 years; 14 compounds predicted by AI with a success rate of over 85% are eagerly awaiting Q3 efficacy readouts. Meanwhile, 5 new BioDAOs including QBIO, Long Covid Labs, Curetopia, SpineDAO, MycoDAO were established, with a total fundraising amount of $8.9 million within the year, injecting continuous fuel into this fast-moving research machine. V2: Transition from DeSci 1.0 to DeSci 2.0 In addition, in August, the BIO team officially launched Bio Protocol V2, aiming to put research funding and execution into "high-speed mode," addressing the pain points of high FDV initial offerings, lack of real-time functionality, and ecosystem dispersion in the DeSci 1.0 stage. The core of V2 lies in four main engines: Low FDV Fixed Price Initial Offering: Drawing lessons from the success paths of Pump.fun and Virtuals, V2 reduces the project's initial valuation to $205,000 FDV, with 35% of tokens sold directly, all raised $BIO injected into the liquidity pool, providing depth and price momentum from the start, creating a strong bond between the community and the project. BioXP Points System: Quantifies behaviors such as staking, LP, on-chain interactions, and social sharing into points, linked to the DeSci Score, with points valid for 14 days, used to allocate quotas for low FDV projects, highly engaged users will continue to have priority opportunities. Staking & veBIO: Staking BIO not only earns point bonuses but also governance voting power; staking other assets within the ecosystem yields a higher point return rate, encouraging support for the entire network. Liquidity Engine: Automatically generate LP after launch, collect a 1% fee per transaction in the secondary market (70% to the project treasury, 30% to the protocol), forming a positive cycle of "active trading - research funding increase - progress promotion - market heat revival." Accelerating Implementation to Embrace the New DeSci Era VitaRNA and VitaFAST are taking DeSci from concept to practical implementation. The two drugs will undergo synchronized trials in the UAE, Singapore, and Switzerland, with the potential to become the first batch of drugs fully funded by DeSci and entering the clinical stage in less than two years at a cost of less than $500,000. This not only breaks the traditional barriers of drug R&D that often take years and cost tens of millions of dollars but also sets a benchmark for on-chain research. Meanwhile, BIO is collaborating with Pfizer on a pilot project to explore a compliant Intellectual Property Tokenization (IPT) model, establishing a new capital circulation and value distribution mechanism for future drug development. Bio Protocol will introduce decentralized scientific research agents, enabling key research processes such as drug screening, clinical operations, and fund allocation to be automated. The upcoming BIO Copilot will transform into a scientist's on-chain research assistant, advancing research into a programmable, scalable, machine-driven stage, breaking free from human bottlenecks and entering an intelligent orbit of high-frequency iteration. In addition, the capital and market flywheel is quietly starting up. The Launchpad 2.0 plan will launch 10-20 low-cap projects in the coming months, covering areas such as Agent, IPT, and research tools, with an average fundraising of $70,000, with Base Chain leading the way, followed closely by Solana. Meanwhile, the "Founding LP Program" is attracting liquidity providers willing to invest over $100,000 in BIO LP, offering participants revenue enhancement, reward points, priority allocation, and exclusive support. Drawing on the high-yield flywheel model of projects like Virtuals, BIO is attempting to ignite a new market heatwave, creating a closed loop of research fund flow, token flow, and information flow, driving the arrival of "Scientific Singularity." What is DeSci? The Decentralized Engine Accelerating Research If the operating logic of traditional science is like a massive steam engine, then Decentralized Science (DeSci) is more like a high-speed electric motor—lighter, faster, and more transparent. In the past, funding for scientific research was almost entirely controlled by government foundations, academic institutions, and large pharmaceutical companies. From project proposal to fund disbursement, the process often involved months or even years of approval procedures; research outcomes were locked behind expensive paywalls, meaning even research projects funded by taxpayers could not be freely accessed by the general public. The storage of research data, ownership of intellectual property, and outcome commercialization were all tightly controlled by centralized institutions and processes. While this model was robust, it also brought inefficiency, conservatism, and innate resistance to disruptive innovation. What DeSci aims to disrupt is precisely this top-down, slow, and closed scientific ecosystem. Through the open ledger of blockchain, it ensures full transparency of fund flows, research progress, and data usage; it replaces small review groups with decentralized autonomous organizations (DAOs), allowing the fate of research projects to be determined by a broader community through voting; and through tokenized incentive mechanisms, early supporters are deeply tied to research outcomes, attracting more funding and talent. This model not only shortens the funding turnover cycle for research but also breaks down barriers between disciplines and regions through global collaboration, providing opportunities for innovative ideas that were previously difficult to fund. In this arena, BIO Protocol is undoubtedly a representative and ambitious player. It not only provides early-stage funding channels for biotech projects but also builds a complete infrastructure that includes project screening, fund-raising, on-chain liquidity management, data transparency, and research automation. Through BIO, researchers can directly "crowdfund" research funding from the global community just like initiating a crypto project; investors can get involved at the initial stage of a project and share profits when research outcomes are commercialized. Compared to traditional research, what BIO aims to achieve is a scientific ecosystem that does not require waiting for funding approval, is not monopolized by a single entity, and allows everyone to participate and benefit. Summary BIO Protocol has experienced dramatic fluctuations from a high-profile launch at the beginning of the year to price bottoms in the middle of the year and is now experiencing a phased rebound with the launch of the V2 version. The new low FDV launch, point staking, and liquidity mechanisms have injected new vitality into the ecosystem and reignited market interest in the DeSci track. However, whether it can sustain the rebound in the future and bring stable gains from new listings still depends on the project's implementation pace and market conditions, with short-term uncertainties still looming.
Bio Protocol Enters V2 Phase, Users Can Earn BioXP Through Staking
Foresight News reports that Bio Protocol has entered the V2 phase and launched Launcher V2, allowing users to sell low-market-cap BioAgents, IP-Tokens, and BioDAOs. In addition, users can stake BIO and DeSci tokens to earn BioXP, and accumulate points by participating in activities. These points can be used to access new sales.
Filled orders
Delivery scenarios
